Minova Life Science

Itrazest-SB65

IN THE TREATMENT OF FUNGAL INFECTION

 

COMPOSITION

Itraconazole BP 65mg/BP 130mg (Supra Bioavailable) Capsules

INDICATION

  • Dermatomycosis
  • Tinea infections
  • Blastomycosis
  • Chromomycosis
  • Sporotrichosis
  • Paracoccidioidomycosis

Itrazest-SB65

  • The orally active antifungal approved by the US-FDA for treating blastomycosis, histoplasmosis, and aspergillosis
  •  Shows a 21% reduced variable bioavailability in comparison to conventional ITZ..
  •  Maintains consistently elevated serum levels, improving effectiveness against persistent dermatophytosis.
  •  Shows a 180% relative bioavailability compared to C-ITZ and an absolute bioavailability of up to 90%.
  •  Achieves an equivalent therapeutic effect with half the dosage compared to conventional Itraconazole.
  •  Exhibits safety and tolerability compared to C-ITZ
Scroll to Top